Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Nat Med · 2025 · PMC11922764 · PMID 39753970

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

This is consistent with previous findings where functionality of T cells from tumors and peripheral blood was directly compared and where T cells from the periphery generally showed a trend toward higher functionality 19 .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.